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Cardiovascular diseases are the major cause of morbidity and mortality worldwide, and there is considerable interest in the role of
dietary constituents and supplements in the prevention and treatment of these disorders. We reviewed the major publications
related to potential eﬀects on cardiovascular risk factors and outcomes of some common dietary constituents: carotenoids,
ﬂavonoid-rich cocoa, tea, red wine and grapes, coﬀee, omega-3 fatty acids, and garlic. Increased intake of some of these has been
associated with reduced all-cause mortality or reduced incidence of myocardial infraction, stroke, and hypertension. However,
although the evidence from observationa ls t u d i e si ss u p p o r t i v eo fb e n e ﬁ c i a le ﬀects for mostofthese foodstuﬀs takenas part of the
diet, potential beneﬁts from the use of supplements derived from these natural products remain largely inconclusive.
1.Introduction
Cardiovascular disease (CVD) has been the major cause of
morbidity and mortality in developed countries over the last
several decades, and the prevalence is increasing dramati-
cally in China and India and other developing countries.
The underlying atheromatous vascular disease manifests
as coronary heart disease (CHD), cerebrovascular disease,
peripheral vascular disease, and subsequent development of
heart failure and cardiac arrhythmias. The major risk factors
for these disorders have been recognised for many years
and include high levels of low-density lipoprotein (LDL)
cholesterol, smoking, hypertension, diabetes, abdominal
obesity, psychosocial factors, insuﬃcient consumption of
fruits and vegetables, excess alcohol, and lack of regular
physical activity, and it was reconﬁrmed recently in the
INTERHEART study that these conventional risk factors
accounted for over 90% of the population attributable risk
for myocardial infarction (MI) [1].
The management of the major risk factors with conven-
tional drugs is eﬀective in reducing cardiovascular events,
and this is supported by extensive evidence from clinical
trials. Recently, there is growing awareness of the place of
dietary factors and herbal medicines in the prevention of
CVD and the possibility of their use in treatment. Much
of this interest centres on the antioxidant vitamins and
the antioxidant properties of food constituents and herbal
materials, but some herbal materials may also improve con-
ventional cardiovascular risk factors or have antithrombotic
eﬀects. The 2005 US Dietary Guidelines and the American
Heart Association have recommended the Diet Approaches
to Stop Hypertension (DASH) diet, but most Americans are
not following these guidelines and their daily consumption
of fruit and vegetables are far short of the recommended
targets [1, 2]. In 2009, it was estimated that only 32.5%
of adults in the United States consumed fruit two or more
times per day and 26.3% consumed vegetables three or more
times per day [3]. In this paper we shall focus on some of
the common food constituents which have been thought to
have beneﬁcial eﬀects on CVD and will discuss some of the
potential mechanisms and results from large clinical trials
and meta-analyses.
2.CommonPotentiallyBeneﬁcial
Food Constituents
Electronic literature searches were performed using MED-
LINE, ISI Web of Knowledge, SCOPUS, and Science Direct
(published from 1970 to 2010). The search terms used2 ISRN Cardiology
were cardiovascular diseases, clinical trial, meta-analysis,
systematic review, carotenoids, cocoa, tea, red wine, grapes,
coﬀee, omega-3 fatty acids, and garlic. A total of 2270
articles were identiﬁed. The bibliographies of all articles thus
located were also scanned for further relevant references.
Three authors (Y. Yang, S. W. Chan, and B. Tomlinson)
extracted all articles independently and evaluated the quality
of the studies and strength of the evidence of clinical
impact using the same standards. Based on the relevance,
strength, and quality of the design and methods, only
the shortlist of the latest studies or representative ﬁndings
were discussed below. Where meta-analyses were available,
these have been discussed rather than the individual studies
included in those analyses. Apart from some important
mechanistic studies, in vitro and animal studies were gener-
ally excluded,as were articles written in languages otherthan
English.
2.1. Carotenoids. Numerous natural carotenoids are present
in fresh fruits and vegetables, and some have been studied
extensively in the prevention of CHD. Most carotenoids
have free radical scavenging eﬀect [4]a n dap o t e n t i a lt o
protect LDL cholesterol against oxidation [5, 6]. Carrots are
ap r i m a r ys o u r c eo fβ-carotene. Elevated levels of serum β-
carotene were associated with a lower risk of cancer and
reduced overall mortality rates [7], and early observational
studies reported an association between a high dietary
intake of β-carotene and reduced incidence of CVD [8, 9].
In a case-control study, the risk of nonfatal acute MI in
women was inversely associated with daily intake of β-
carotene-containing diet [10]. In the Rotterdam study, a
population-based cohort study in the elderly, dietary intake
of β-carotene was inversely associated with the risk of MI
[11]. Interestingly, in the American Health Professional’s
Study conducted in 39,910 US males, carotene intake was
associated with a lower risk of CHD among current smokers
but not nonsmokers [12].
Although many epidemiologic studies have reported an
association between β-carotene and the risk of CVD, several
large randomized trials did not reveal any reduction in CVD
with β-carotene consumption. For instance, the MRC/BHF
Heart Protection Study showed no beneﬁt from β-carotene
20mg daily, in combination with vitamin E 600mg and
vitamin C 250mg, on morbidity or mortality in high-risk
individuals[13].Inthe α-tocopheroland β-carotene (ATBC)
study conducted in 1,862 male smokers who had a previous
MI, there were no signiﬁcant diﬀerences in the number of
major coronary events between any supplementation group
and the placebo group. Moreover, the risk of fatal CHD
was increased in the β-carotene and combined α-tocopherol
and β-carotene groups compared to the placebo group
[14]. Likewise, the Women’s Antioxidant Cardiovascular
Study (WACS) found no CVD risk reduction in women at
high risk with β-carotene 50mg every other day, or with
vitamin C 500mg daily or vitamin E 600 IU every other
day [15]. The prospective evaluation of the relation between
vegetable intake and CHD risk in the Physicians’ Health
Study concluded that the consumption of vegetables rich in
carotenoids was associated with a reduced risk of CHD [16],
but after 12 years of followup there was no impact from
supplementationofβ-carotene50mgalternatedaysonCVD,
cancer, or overall mortality among primarily nonsmokers
[17].
Lycopene, one of the most common carotenoids in the
human diet, has twice the antioxidant activity of β-carotene
[18]. Tomatoes are the best source of lycopene, which is the
focus of research as a precursor to vitamin A. A diet rich
in tomatoes, tomato products, and lycopene is associated
with a lower risk of CHD [19]. Epidemiological studies
and supplementation clinical trials suggested a reduction
in CVD risk but not all studies have conﬁrmed this. A
multicentre case-control study suggested that lycopene may
contribute to the protective eﬀect of vegetable consumption
on MI risk [20]. The Kuopio Ischaemic Heart Disease Risk
FactorStudyconductedin1,028 middle-aged menineastern
Finland showed that subjects with low concentration of
serum lycopene concentration had a signiﬁcantly higher
mean intima-media thickness of the common carotid artery
(CCA-IMT) and higher maximal CCA-IMT than did the
other men [21]. Conversely, in the Physicians’ Health Study,
no association between increasing concentrations of plasma
lycopene and the risk of CVD was found [22]. A recent
review of the controlled clinical studies with lycopene in
well-deﬁned subject populations found no deﬁnite evidence
for CVD prevention [23]. Representative observational and
intervention studies on the association of carotenoids with
t h er i s ko fC V Da r es u m m a r i z e di nTable 1.
Apart from carotenoids and lycopene, many fruits
and vegetables are also rich in glutathione. Glutathione
and glutathione-1 peroxidase provide important antioxi-
dant eﬀects that may prevent CVD. A prospective study
conducted in 636 patients with suspected coronary artery
disease (CAD), with a median followup period of 4.7 years
(maximum, 5.4), suggested that increasing glutathione-1
peroxidase activity might lower the risk of cardiovascular
events [24]. A thorough review on the relations between
plasma glutathione levels and CVD suggested that reduced
plasma total glutathione levels are a risk factor for CVD
especially for cerebral small vessel disease [25].
Currently, it seems logical that a higher dietary intake of
fruit and vegetables rich in carotenoids may play a role in
the prevention of morbidity and mortality associated with
CVD. However, the evidence that speciﬁc supplements are
beneﬁcial is controversial, and the underlying mechanisms
are not clear. Further studies are in progress to determine
the usefulness of the consumption of carotenoids in the
prevention and treatment of CVD.
2.2. Flavanol-Rich Cocoa. Flavanol-rich foods are common
in the spectrum of the human diet and ﬂavanols are present
in items such as wine, tea, various fruits, and certain
vegetables. Among these, cocoa and cocoa-derived products,
such as cocoa powder and chocolate, are representative
foods containing natural ﬂavanols that have received much
attention. Cocoa and cocoa-derived products are derived
from the fermented, roasted, and industrially processed
seed of the Theobroma cacao tree. The Kuna Indians in
Panama have a very high intake of ﬂavanol-rich cocoa, whichISRN Cardiology 3
Table 1: Observational and intervention studies of the associationof carotenoids with the risk of cardiovascular disease.
Authors Type of study Subjects Methods Findings
Cook et al. [15] Randomized controlled
factorial
8,171 female health
professionals aged ≥40
with a history ofCVD
or ≥3C V Dr i s kf a c t o r s
with followup of 9.4
years
Vitamin C (500mg/d), E
(600 IU every other
day), or β-carotene
(50mg every other day)
No association between
vitamin C, E or
β-carotene on
cardiovascular events.
Heart Protection Study
Collaborative Group
[13]
Randomized
placebo-controlled
20,536 UK adults aged
40–80 with CHD, OAD,
or DM with followup of
5y e a r s
β-carotene 20mg/d,
vitamin E 600mg/d, and
vitamin C 250mg/d, or
placebo
No association between
β-carotene consumption
and the 5-year mortality
from, or incidence of,
any type of vascular
disease
Hennekens et al. [17]
Randomized,
double-blind,
placebo-controlled
22,071 US male
physicians aged 40–84
without heart disease,
stroke or cancer with
followup of 12 years
β-carotene 50 mg/d or
placebo
No association between
β-carotene
supplementation and the
incidence of CVD, or
death from all causes
among primarily
nonsmokers.
Klipstein-Grobusc et al.
[11]
Community-based
prospective
4,802 subjects aged
55–95
Questionnaire and
interview with trained
dietitian
An inverse association
between high dietary
β-carotene intake and
risk of MI
Kohlmeier et al. [20] Multicenter case-control
1,387 subjects from 10
European countries with
MI or controls
Assay of 3 carotenoids in
adipose tissue biopsies
Adipose tissue lycopene
level was best predictor
of MI risk
Rapola et al. [14]
Randomized,
double-blind,
placebo-controlled
1,862 male smokers aged
50–69 with previous MI
with follow-up of 5.3
years
α-tocopherol (50mg/d),
β-carotene (20mg/d),
both, or placebo
Supplementation of
β-carotene increased the
risk of fatal coronary
events
Rimm et al. [12]P r o s p e c t i v e 39,910 US male health
professionals aged 40–75
Interview using
questionnaire
Higher carotene intake
was associated with
lower risk of CHD only
among current smokers
Rissanen et al. [21] Cross-sectional 1,028 men aged 46–64 in
eastern Finland
Blood assayand
CCA-IMT measurement
Lowest quartile of serum
lycopene had higher
CCA-IMT
Sesso et al. [22] Prospective nested
case-control study
499 with CVD and 499
controls male US
physicians
Blood assayand
self-reported data to a
standard questionnaire
No association between
plasma lycopene and the
risk of CVD
Tavani et al. [10]C a s e - c o n t r o l s t u d y
433 Italian women with
nonfatal AMI and 869
controls
Interview on dietary
β-carotene intake using a
structured questionnaire
The risk of AMI was
inversely related to
β-carotene intake for the
highest quintile of intake
compared to the lowest
AMI: acute myocardial infarction; CCA-IMT: intima-media thickness of the common carotid artery; CHD: coronary heart disease; CVD: cardiovascular
d i s e a s e ;D M :d i a b e t e sm e l l i t u s ;M I :m y o c a r d i a li nfarction; OAD: occlusive arterial disease.
may be related to them having low blood pressure levels,
reduced frequency of cardiovascular events, and longer life
expectancythanotherPanamanians [26].Incocoaand cocoa
products, the ﬂavanols include monomeric forms (cate-
chins) and polymer forms (procyanidins). Monomers bind
together by links between C4 and C8 and form dimers,
and oligomers even up to decamers [27]. Procyanidins,
also known as condensed tannins, combine with salivary
proteins which cause the bitterness of cocoa as well as the
astringent character of some fruits [28]. The major co-
coa catechins include (+)-catechin, (−)-epicatechin, (+)-
gallocatechin, and (−)-epigallocatechin. These monomers
bind together to form procyanidin B1, procyanidin C1,
procyanidin D, and so forth.
Data from cell culture and animals studies suggest that
cocoa may have antioxidant and anti-inﬂammatory eﬀects
[37]. An in vitro study examined nitric oxide (NO) levels
in human umbilical vein endothelial cells under diﬀerent4 ISRN Cardiology
Table 2: Observational studies of the associationof ﬂavanol-rich food with the risk of cardiovascular disease.
Authors Type of study Subjects Methods Findings
Cocoa
Buijsse et al. [29]P r o s p e c t i v e
19,357 Germans aged
35–65 years free of MI,
stroke and not on
antihypertensive
medication with mean
followup of 8 years
Interview using questionnaire
on consumption frequency of
50g
milk/dark/white/unspeciﬁed
chocolate bars
Highest quartile of
chocolate consumption
(mainly milk and dark
chocolate) had lower
relative risk of the
combined outcome of
MI and stroke
Janszky et al. [30] Population-based
case-control
1,169 nondiabetic and
newly diagnosed ﬁrst
AMI patients with
followup of 8 years
Questionnaire on
consumption frequency of
50g chocolate (rangingfrom
never to twice or more per
week)
Chocolate consumption
reduced cardiac
mortality in a
dose-dependent manner
Mostofsky et al. [31]P r o s p e c t i v e
31,823 women aged
48–83 in Sweden
without DM, HF or MI
with followup of 9 years
Questionnaire on chocolate
consumption frequency
(rangingfrom never to ≥3
times/d)
Moderate (1–3
times/month) habitual
chocolate intake was
associated with a lower
rate of HF
hospitalization or death
but there was no
protection with intake
≥1t i m e / d
Tea
Kuriyama et al. [32] Population-based
prospective
40,530 Japanese aged
40–79 without history of
stroke, CHD, or cancer
with followupof11 years
Questionnaire on green tea
consumption frequency
(rangingfrom never to > 5
cups/d)
Compared with those
consumed < 1c u p / d
green tea, consumption
of ≥ 5c u p s / dh a dl o w e r
risk of all-cause and
CVD mortality, and this
eﬀect was stronger in
women
Nakachi et al. [33]P r o s p e c t i v e
8,497 residents in Japan
aged over 40 with
followup of 11 years
Questionnaire on green tea
consumption frequency
(rangingfrom <3t oo v e r1 0
cups/d)
Consumption of > 10
cups/d green tea
decreased the relative
risk of death from CVD
Tanabe et al. [34]P r o s p e c t i v e
6,358 Japanese aged
40–89 without a history
of stroke or heart disease
with followup of 5 years
Questionnaire on tea
consumption frequency
(rangingfrom ≤ several cups
a week to > 5c u p s / d )
Green tea consumption
of > several cups every
2-3 days was associated
withreduced risk oftotal
stroke incidence
Yang et al. [35]P r o s p e c t i v e
1,507 Taiwanese aged
≥ 20 without
hypertensive history
Interview using questionnaire
on green tea consumption
frequency (ranging from
nonhabitual< 120mL/d to
≥ 600mL/d) and standard
measurement of
anthropometry and blood
pressure
An inverse association
between the newly
diagnosed hypertension
risk and habitual tea
consumption
Red wine and grapes
Gronbaek et al. [36] Community-based
prospective
13,285 subjects in
Denmark aged 30–70
with followup of 10–12
years
Questionnaire on alcohol
(beer, wine, or spirit)
consumption
Low to moderate intake
(3–5 glasses) of wine
reduced the risk of death
from CVD and
cerebrovascular disease
AMI: acute myocardial infarction; CHD: coronary heart disease; CVD: cardiovascular disease; DM: diabetes mellitus; HF: heart failure; MI: myocardial
infraction.ISRN Cardiology 5
treatment conditions. It found that epicatechin, a ﬂavan-
3-ol, scavenged free radicals, inhibited NADPH oxidase
activity, and preserved the bioavailability of NO [38]. An
animal study carried out on rabbit aortic rings showed
that polymeric procyanidins derived from cocoa produced
an endothelium-dependent relaxation which was mediated
by activation of endothelial NO synthase [39]. In another
study using cultured endothelial cells, cocoa decreased the
activity of arginase which augmented the local levels of
L-arginine, the precursor for NO synthesis [40]. It has
been demonstrated that oral administration of L-arginine
improves endothelium-dependent dilation in the forearm
conduit arteries in patient with hypercholesterolemia [41].
In a prospective, double-blind, randomized crossover trial,
long-term oral administration of L-arginine improved
endothelium-dependent dilation and reduced monocyte
adhesion to the endothelium in young men with coronary
disease [42].
Accumulating epidemiological evidence suggests that
ﬂavanol-rich food such as cocoa has potential cardiopro-
tective eﬀects which might be attributed to improvements
of cardiovascular risk factors (Table 2). In healthy male
adults, daily intake of ﬂavanol-rich cocoa drink over 1
week produces a sustained increase in FMD [43]. This
long-term result on FMD is probably induced by elevated
level of endothelial NO synthase (eNOS), which is further
corroboratedbyin vitro data.In a double-blind,randomized
study,consumptionofchocolateimprovedcoronaryvascular
function and reduced platelet adhesion, and these beneﬁcial
eﬀects were coupled with reduced serum oxidative stress
measures and changes in serum epicatechin concentration
[44].
A prospective cohort study from Sweden with followup
of 31,823 women over 9 years concluded that moderate
habitual chocolate intake was associated with a lower inci-
dence of heart failure. However, the protective association
was not observed with greater intake of chocolate per
day [31]. An observational study in a cohort of 19,357
German adults with followup of 8 years revealed that
chocolate consumption lowered the risk of the combined
outcome of MI and stroke which was partially due to
reduced blood pressure [29]. It has also been reported
that chocolate consumption is correlated with lower cardiac
mortality in patients who survived a previous acute MI
[30].
A recent meta-analysis, which included ten controlled
studies involving normal adults or patients with hyper-
tension and treated with cocoa products for a short-term
ranging from 2 to 18 weeks, concluded that ﬂavanol-rich
cocoa products taken for 2–18 weeks reduce both systolic
(−4.5mmHg) and diastolic (−2.5mmHg) blood pressures
[45].Furthermore,ameta-analysisofrandomizedcontrolled
trials showed that chocolate or cocoa produced both acute
and chronic eﬀects on FMD but not on LDL cholesterol and
high-density lipoprotein (HDL) cholesterol concentrations
[46]. Several trials indicate that cocoa or chocolate inhibits
platelet function [47, 48].
Evidence for cardiovascular beneﬁts of cocoa ﬂavanols
has come largely from short-term and uncontrolled studies
and, therefore, additional well-designed, long-term clinical
trials ofcocoasupplementationarerequired [49].The mech-
anisms described above may partially explain the positive
eﬀects of ﬂavanol-rich foods on CVD. Whether cocoa may
possess antioxidant activity requires further investigation.
It is important to consider that many chocolate-containing
products also contain large amounts of fat and sugar which
might negate any potential beneﬁt from the ﬂavanol content
of the product.
2.3.Tea. Teaisoneofthemostpopularbeveragesworldwide.
It contains polyphenols in amounts similar to those found
in red grapes. Tea is the product of the leaves and leaf
buds of Camellia sinensis. Tea can be classiﬁed into 3 main
categories according to the degree of fermentation: fully-
fermented black tea, semifermented Oolong tea, and unfer-
mented green tea. The polyphenolic compounds, mainly
catechins, contained in green tea are associated with its
cardiovascular protective eﬀect. The major tea catechins
include (−)epicatechin (EC), (−)-epigallocatechin (EGC),
(−)-epicatechin-3-gallate (ECG), and (−)-epigallocatechin-
3-gallate (EGCG). Catechins inhibit the expression of
inducible NO synthase (iNOS) [50, 51] and reduce inﬂam-
mation and ROS-generating enzymes [52, 53]. They also
induce apoptosis of monocytes [54], lower lipids levels [55],
reduce oxidative stress [50], inhibit platelet aggregation [56],
and decrease apolipoprotein (Apo) B levels and increase
the ratio of ApoA-1/ApoB [57]. The galloyl group may
also exert cardiovascular protective eﬀects via multiple
cellular pathways and transcriptional factors involved in the
cardiovascular system [58].
The association of green tea consumption with cardio-
vascular protection has been well documented in observa-
tional studies (see Table 2). A long-term study performed in
Japan showed that daily consumption of 10 cups green tea
was associated with a reduction in cardiovascular mortality
in men [33]. In the Ohsaki study, a population-based
prospective cohort study, green tea consumption was asso-
ciated witha reductionin CVDmortality [32]. A prospective
cohort study in 6,358 Japanese followed up for 5 years
revealed an inverse correlation of green tea consumption
and the risk of stroke incidence [34]. This association was
further conﬁrmed by a meta-analysis on 9 studies involving
4,378 individuals from diﬀerent countries [59]. However,
in a study of 2,855 Japanese, no association between green
tea consumption and cardiovascular mortality was observed
[60]. In a review of randomized controlled trials on the
association between green tea and CVD risk proﬁles, only 17
out of 30 studies have reported beneﬁcial eﬀects of green tea,
11studiesshowedneutraleﬀectswhereas2studiesconcluded
harmful eﬀects [61].
The increase in blood pressure shortly (30–90 minutes)
after green tea consumption has been examined in several
studies [62–64]. It is noteworthy that the increase in blood
pressure is even greater than that produced by the same
amount of caﬀeine administered alone [64]. Conversely,
long-termconsumptionofteamay havea beneﬁcialeﬀecton
blood pressure. In a cross-sectional study of 218 Australian
women over 70 years old, long-term regular consumption6 ISRN Cardiology
of tea was associated with a lower systolic blood pressure
and lower diastolic blood pressure [65]. In a cohort study
conducted in 1,507 Chinese over 20 years old in which
the mean blood pressure was carefully multiadjusted, daily
consumptionof123–599mL orover600mL greenoroolong
tea reduced the risk of developing hypertension by 46% and
65%, respectively, compared with non-habitual tea drinkers
[35]. However, a larger cross-sectional study conducted in
3,336 Japanese males showed that green tea consumption
failed to alter blood pressure [66].
Consumption of green tea has also been associated with
lower levels of total cholesterol and LDL cholesterol [46],
but without eﬀects on serum HDL cholesterol and triglyc-
erides [67]. A double-blind, randomized, controlled study
conducted in 40 overweight Japanese children suggested
that 24-week consumption of a drink made from green
tea eﬀectively reduced the LDL cholesterol level although
the eﬀect may have been related to weight loss [68]. A
randomized, double-blind, placebo-controlled study in 111
healthy adult volunteers revealed that consumption of green
tea (standardized and deﬁned decaﬀeinated) for 3 weeks
reduced LDL cholesterol levels[69]. However, several studies
failed to ﬁnd a signiﬁcant correlation between green tea
consumption and HDL cholesterol levels [69–71].
The majority of studies with tea have used green tea,
but a few studies have been done using black tea and
oolong tea. Short- and long-term consumption of black tea
was shown to reverse endothelial vasomotor dysfunction
but did not reduce ex vivo platelet aggregation in patients
with CHD [72, 73]. Potential protective eﬀects of green
tea and black tea against CVD and cancer were attributed
to the polyphenolic compounds, particularly the catechin,
epigallocatechin gallate (EGCG) in green tea, and theaﬂavins
in black tea. The processing of tea to produce black tea
results in the conversion of catechins into theaﬂavins and
thearubigins, but these also appear highly potent in NO
production and vasorelaxation [74]. The concentrations of
catechins including EGCG in black tea are much lower than
that in green tea [75] but the theaﬂavins in black tea also
providean antioxidant eﬀect which in some studies is similar
to that of green tea [76]. In an epidemiological study on
17,228 subjects (mean age, 59.5 years) initially free of CVD
and cancer from the College Alumni Health Study, black tea
consumption was not associated with a reduced risk of CVD
[77]. In a prospective study of 76,979 healthy individuals
aged 40–79 years in Japan, consumption of coﬀee, green tea,
and oolong tea and total caﬀeine intake were all associated
withreducedrisksofmortalityfromCVD[78].Asmallstudy
performed in The Netherlands, which studied the use of
dietary bioﬂavonoids, phenolic acids, and quercetin, showed
that there was a reduction in the incidence of heart attack
and sudden death in the elderly men aged 65–84 years with
a higher ﬂavonoid intake and one of the major sources of
ﬂavonoid intake (61%) was from tea [79].
2.4. Red Wine and Grapes. The traditional French diet is
high in saturated fats, but residents of France have a lower
incidence of CAD than Americans, the so-called French
paradox [80]. The typical French diet includes regular intake
of fresh fruit and vegetables that contain phytonutrients
which have antioxidant eﬀects and may retard atherogenesis
and thrombosis. However, consumption of red wine may be
another protective factor. The rich polyphenolic content of
red wine has made it a popular subject for consideration
i nt h ep o s s i b l ep r e v e n t i o no fc a n c e ra n dC V D[ 81]. Daily
consumption of mild to moderate (1-2 drinks) amounts of
red wine is thought to produce beneﬁcial eﬀects on CVD,
which have been considered by some to provide the basis for
the French paradox.
Red wine contains many polyphenolic compounds
including nonﬂavonoids and ﬂavonoids [82]. These com-
pounds have antioxidant, anti-inﬂammatory, and potential
antiatherogenic eﬀects. A study of the antioxidant activity of
red wine in volunteers showed that two glasses of red wine
before food had antioxidant activity lasting for at least 4
hours [83]. Red wine increases antioxidant activity through
the ﬂavonoid-polyphenol eﬀect. Grapes and wines also
contain catechol compounds which possess antioxidative
eﬀects.
Part of the beneﬁt of red wine may be from the alcohol
content. The INTERHEART study, a very large case-control
study conducted in 15,152 patients who had experienced
an acute MI and 14,820 age- and sex-matched controls,
has shown that regular consumption of alcohol (3 or more
times a week) had a cardioprotective eﬀect against MI
[1]. However, in the prospective Copenhagen Heart study,
low to moderate consumption of wine was associated with
lower mortality from CVD and cerebrovascular disease and
other causes whereas beer consumption failed to aﬀect
mortality and a similar intake of spirits appeared to increase
the risk [36]( Table 2). In a meta-analysis including 13
studies and 209,418 participants, moderate red wine intake
reduced the atherosclerotic risk by 37% and there was a
similar, but smaller, association with reduced risk in beer
consumption studies, again suggesting that red wine may
have an additional beneﬁt beyond the alcohol content [84].
Moderate red wine consumption has beneﬁcial eﬀectson
some cardiovascular risk factors, particularly HDL choles-
terol and possibly ﬁbrinogen, which are not seen with
red grape extract so those beneﬁts may be attributed to
the alcohol content and it has been suggested that any
beneﬁcial eﬀect of red wine compared to other alcoholic
beverages may be related to other life-style confounders
rather than the nonalcohol components of red wine [85].
Several small studies have shown beneﬁcial eﬀects from
the other components of red wine. A double-blind, cross-
over study conducted in 15 CAD patients showed that
acute consumption of either 250mL regular or alcohol-
free red wine signiﬁcantly improved the arterial stiﬀness
and wave reﬂections [86]. Interestingly, administration of
alcohol-free red wine produces an improvement in various
CVD risk parameters in some other studies. In line with
these results, two studies showed that acute consumption
of alcohol-free red wine caused an improvement of brachial
artery ﬂow-mediated vasodilation [87, 88]. However, some
studies failed to show any additional protective eﬀects of red
wine consumption compared with other types of alcoholic
beverages [89, 90].ISRN Cardiology 7
Several studies have examined the potential beneﬁts
of speciﬁc components in red wine such as resveratrol
and oligomeric proanthocyanidins in reducing CVD risk.
Resveratrol is mainly found in grape skin, and, thus,
signiﬁcant amounts of resveratrol are present in red wine.
It has been suggested that it has cardioprotective eﬀect
since it activates platelet NO synthetase [91]a n di n h i b i t s
LDL oxidation [92–94], inﬂammation [95], production of
reactive oxygen species [96], and platelet aggregation [97].
Evidence from animal studies suggests that resveratrol exerts
itcardioprotectiveeﬀectby attenuating theproinﬂammatory
eﬀects invoked by platelet-activating factor [98] and upregu-
lating the expression for iNOS, eNOS, VEGF, and KDR [99].
The beneﬁcial eﬀects of moderate wine intake on ischaemic
CVD may be explained by this [100]. Many studies on
resveratrol have been conducted in cultured cells and animal
models. However, there is currently no deﬁnite evidence that
resveratrol has cardioprotective eﬀects in humans, and as the
oral bioavailability of resveratrol in man is extremely low
it is diﬃcult to assess the true physiological signiﬁcance of
resveratrol [101].
Oligomericproanthocyanidins arefreeradicalscavengers
[102] which inhibit lipid peroxidation [103]a n dh a v e
anti-inﬂammatory and antiallergenic properties [104]. Like
carotenoids, they are found predominantly in brightly
coloured fruits and vegetables and represent a safe source
of polyphenols and quercetin, the latter being believed to
be particularly active in preventing LDL oxidation [105].
In a placebo-controlled cross-over study with quercetin
150mg daily supplementation for 6 weeks in overweight or
obese subjects with metabolic syndrome traits, there was a
decrease in systolic blood pressure by 2.6mmHg, a decrease
in plasma concentrations of atherogenic oxidised LDL, and
a small but signiﬁcant decrease in serum HDL cholesterol
concentrations, although the ratio of LDL:HDL-cholesterol
was unchanged [106].
The Physician’s Health Study did not show any associa-
tion between intake of ﬂavonoids and all CAD events [107].
The Kuopio Ischaemic Heart Disease Risk Factor Study
concludedthata high intakeofﬂavonolsand themean CCA-
IMT were negatively associated [108]. The optimal amount
and form of ﬂavonoids in the diet are not known, and
some of these compounds have rather low bioavailability. In
spite of the uncertainties, many ﬂavonoids are available as
food supplements in doses as high as 500 and 1000mg, an
amount 10 to 20 times the daily intake of a typical vegetarian
diet. With the currently available information, patients with
C A Da n dt h o s ea tr i s ko fC V Dm a yb ee n c o u r a g e dt o
include moderate red wine intake in their diet, but current
research ﬁndings do not support the use of supplemental
ﬂavonoids derived from grapes or red wine, and further
prospective controlled studies are needed to identify whether
such supplements may be beneﬁcial.
2.5. Coﬀee. Coﬀee from the seeds of plants of the Coﬀea
genus is the most important overall source of caﬀeine in
adults although caﬀeine is also present in tea, chocolate,
and certain soft drinks [109]. Coﬀee also contains other
biologically active compounds, including chlorogenic acid,
and the diterpene alcohols cafestol and kahweol, which
may have long-term eﬀects on risk factors for CHD.
A c u t ei n t a k eo fc o ﬀee has a number of unfavorable car-
diovascular eﬀects, including increases in blood pressure,
circulatingcatecholamines,arterialstiﬀness,andimpairment
of endothelium-dependent vasodilation which are probably
attributable to caﬀeine [110]. However, studies examining
the association between coﬀee consumption and CHD have
been inconclusive, which may reﬂect the complex mixture of
compoundsthatmayhaveeitherbeneﬁcialorharmfuleﬀects
on the cardiovascular system [111].
Acute intake of coﬀee raises systolic and diastolic blood
pressure and slightly reduces heart rate, which is probably
due to the eﬀect of caﬀeine antagonizing the adenosine A1
and A2A receptors [112]. Coﬀee also has a cholesterol-raising
eﬀect which appears to be related to diterpenes present
in boiled coﬀee, and this may contribute to the risk of
CHD associated with unﬁltered coﬀee consumption [113].
Coﬀee consumption is associated with higher plasma total
homocysteine concentrations which may increase the risk
of CVD, and it was shown that caﬀeine was only partly
responsible for the homocysteine-raising eﬀect of coﬀee
[114].However,severalstudieshaveshown thatcoﬀeeintake,
including decaﬀeinated coﬀee, was inversely associated with
the risk of developing type 2 diabetes mellitus [115], and
another study showed that potentially black tea, but not
green tea, in addition to coﬀee may also reduce the risk of
type 2 diabetes mellitus [116].
A study of the association between coﬀee consumption
and risk of acute nonfatal MI found that the polymorphism
i nt h ec y t o c h r o m eP 4 5 01 A 2( C Y P 1 A 2 )e n z y m er e s u l t i n g
in the variant CYP1A2
∗1F with “slow” caﬀeine metabolism
modiﬁed the association so that increased intake of coﬀee
was only associated with an increased risk of nonfatal MI
amongindividualswithslowcaﬀeinemetabolism, suggesting
that caﬀe i n ew a sam a j o rf a c t o ri nt h ea s s o c i a t i o n[ 117].
Several studies have examined the relationship between
coﬀee intake and cardiovascular events and mortality with
conﬂicting results. A recent long-term followup of partici-
pantsintheHealthProfessionalsFollowupStudyandNurses’
Health Study found that regular coﬀeeconsumption was not
associated with an increased mortality rate in either men or
women and there appeared to be a modest beneﬁt of coﬀee
consumption on all-cause and CVD mortality [118]. Alower
risk of CHD among moderate coﬀee drinkers might be due
to antioxidants found in coﬀee.
2.6. Omega-3 Poly-Unsaturated Fatty Acids. Early reports
of the very low incidence of CHD in Greenland Eskimos
[124] which was believed to be related to the high intake of
seafood containing long-chain omega (n)-3 polyunsaturated
fatty acids (n-3 PUFA) prompted many studies in other
populations that have supported the theory that marine n-
3 PUFAs protect against thrombosis, atherosclerosis, and
CHD. The 3 major dietary n-3 PUFAs include eicosapen-
taenoic acid (EPA), docosahexaenoic acid (DHA), and α-
linolenic acid (ALA). Some prospective cohort studies and
randomized control trials in secondary prevention have
found that consuming ﬁsh or ﬁsh oil containing EPA and8 ISRN Cardiology
Table 3:Interventionstudies oftheassociationofomega-3poly-unsaturated fattyacidsconsumptionwiththeriskofcardiovasculardisease.
Authors Type of study Subjects Interventions Findings
GISSI Prevenzione
investigators [119, 120]
Multicenter,
randomized, controlled,
open-label, parallel
11,323 patients surviving
recent (≤3m o n t h s )M I
with followup of 3.5
years
Supplements of n-3
PUFA (1g/d), vitamin E
(300mg/d), both, or
none
Early protection of n-3
PUFA on all- cause
mortality especially
sudden cardiac death;
over 3.5 years,
supplementation with
n-3 PUFA was associated
with lower risk of death,
nonfatal MI, and stroke.
Svenssonet al. [121]
Randomized,
double-blind,
placebo-controlled
206 patients with CVD
and treated with stable
chronic hemodialysis
with followup of 2 years
Supplements of n-3
PUFA (1.7g/d), or
control (olive oil)
Consumption of n-3
PUFA reduced the
incidence of MI but had
no eﬀect on all- cause
mortality or total
cardiovascular event
Tavazzi [122]
Multicenter, randomized
double-blind,
placebo-controlled
6,975 patients aged ≥18
with chronic heart
failure with followup for
am e d i a no f3 . 9y e a r s
n-3 PUFA 1g/d or
placebo
Consumption of n-3
PUFA was associated
with reduced all- cause
mortality, hospital
admissions for CVD
Yokoyama [123]
Randomized, controlled,
open-label, blinded
endpoint
18,645 patients with a
total cholesterol of
≥6.5mmol/L with
followup of 5 years
Daily consumption of
1800mg of EPA with
statin or statin only
Daily consumption of
EPA with statin reduced
unstable angina and
nonfatalcoronary
events.
CVD: cardiovascular disease; EPA: eicosapentaenoic acid; GISSI: Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico; MI: myocardial
infraction; n-3 PUFA: omega (n)-3 polyunsaturated fatty acids.
DHA was associated with a decreased cardiovascular death
rate, whereas the consumption of vegetable oil-derived ALA
may not be as eﬀective [125], but not all studies results
are consistent. One systematic analysis concluded that long-
chain and shorter-chain omega 3 fats do not have a clear
eﬀect on total mortality, combined cardiovascular events, or
cancer [126].
Various studies show that doses >3g/d, EPA plus DHA
can improve many CVD risk factors, including reducing
plasma triglycerides, blood pressure, platelet aggregation,
and inﬂammation, along with improving vascular reactivity.
A recent review considered the possible diﬀerence between
whole ﬁsh and ﬁsh oil supplements and concludedthat there
was an association between dietary intake of n-3 PUFAs
or ﬁsh with a reduced risk of subclinical atherosclerosis
[127]. A randomized controlled trial of patients awaiting
carotid endarterectomy indicated that n-3 PUFAs from ﬁsh
oil enhanced the stability of atherosclerotic plaques [128].
However, it has been suggested that the therapeutic eﬀects
on CVD mortality could be attributed to a suppression of
fatal arrhythmias rather than stabilization of atherosclerotic
plaques [125, 129].
A meta-analysis on the eﬀect of n-3 PUFAs in ﬁsh oil
on blood pressure, which examined 31 controlled trials,
concludedthat greater consumption of n-3 PUFAs was asso-
ciated with greater reduction in blood pressure, particularly
in hypertensive subjects and those with clinical atheroscle-
rotic disease or hypercholesterolemia [130]. In a randomized
open-label, blinded endpoint study, which evaluated 18,645
patientswith a totalcholesterol of6.5mmol/L orabove,daily
consumption of 1800mg EPA reduced posttreatment LDL
cholesterol, unstable angina, and nonfatal coronary events
[123]. A systematic review of 47 studies concluded that daily
consumption of EPA and/or DHA (average 3.25g) produces
a signiﬁcant reduction of triglycerides levels but not total,
HDL, or LDL cholesterol in hyperlipidemic subjects [131].
Accumulating evidence has suggested that consumption
of n-3 PUFAs decreases the risk of cardiovascular mortality
and sudden cardiac death especially in patients with a
history of MI. In the diet and reinfarction trial (DART),
which involved 2,033 men recovered from MI, there was
a signiﬁcant reduction of total mortality in subjects who
consumed 2-3 portions of fatty ﬁsh daily [132]. The GISSI-
Prevenzione trial, which examined 11,323 patients who
had experienced MI within 3 months, showed that daily
intake of 1g n-3 PUFA supplementation was associated
with a signiﬁcant reduction in all-cause and cardiovascular
mortality, especially risk of sudden cardiac death [119]. The
subsequent analysis to assess the time course of the beneﬁt
of n-3 PUFAs in the GISSI-Prevenzione trial found the
survival curves for n-3 PUFA treatment diverged early after
randomization, and total mortality was signiﬁcantly lowered
after 3 months of treatment suggesting that this early beneﬁt
supported the hypothesis of an antiarrhythmic eﬀect [120].
In the GISSI-HF trial, patients with chronic heart failure of
New York Heart Association class II-IV receiving n-3 PUFAISRN Cardiology 9
1g daily showed small but signiﬁcant reductions in all-cause
mortality and hospital admissions for cardiovascular reasons
[122].
In a randomized, double-blind,placebo-controlled study
which was conducted in patients treated with chronic
haemodialysis, consumption of n-3 PUFAs did not reduce
the risk of cardiovascular event and death [121]. However,
some clinical trials with increased consumption of ﬁsh oil
showed an increase in sudden death in men [133, 134]. A
review on the pro- and antiarrhythmic properties of n-3
PUFAs suggested that n-3 PUFAs may be antiarrhythmic
under conditions that favour triggered activity but may
also facilitate reentrant arrhythmias leading to sudden death
and advice to increase intake of n-3 PUFA supplements
or fatty ﬁsh should be tailored to individual patients with
respect to the arrhythmogenic mechanisms associated with
theunderlyingpathology[135].However,arecentsystematic
review and meta-analysis on the eﬀects of ﬁsh oil DHA
and EPA on mortality and arrhythmias, which examined 12
studies totalling 32,779 patients, concluded that ﬁsh oil sup-
plementation was associated with a signiﬁcant reduction in
deaths from cardiac causes but had no eﬀect on arrhythmias
or all-cause mortality and the optimal formulations for EPA
and DHA remain unclear [136].
Most recently, a large study from Denmark following
57,053 middle-aged men and women for 7.6 years found
that a modest intake of fatty ﬁsh was associated with a
lower risk of acute coronary syndrome (ACS) with beneﬁts
seen for intakes >6 g of fatty ﬁsh per day but no obvious
additional beneﬁt for higher intakes and no beneﬁt from
intake of lean ﬁsh [137]. There were few cases of ACS in
women and no consistent associations with ﬁsh intake were
observedinthewomen.Studiespertaining totheeﬀectsofn-
3PUFAsupplementsoncardiovascularrisksaresummarized
in Table 3. Current recommendations from the American
Heart Association are that everyone should eat oily ﬁsh
twice per week for primary prevention and that people with
established CHD should take 1g/d of EPA and DHA from
oily ﬁsh or supplements [138, 139].
2.7. Garlic (Allium sativum). For centuries garlic has been
valued for its medicinal properties. As an herbal medicine
it has been more closely examined than many others. Much
research has focused on garlic for preventing atherosclerosis.
Multiple beneﬁcial cardiovascular eﬀects have been found
including lowering of blood pressure, inhibition of platelet
aggregation, enhancement of ﬁbrinolytic activity, reduction
in cholesterol and triglyceride, and protection of the elastic
properties of the aorta [140].
The intact cells of garlic bulbs contain an odourless,
sulphur-containing amino acid allinin. When garlic is
crushed, allinin comes into contact with allinase which
converts allinin to allicin. Fresh garlic releases allicin in the
mouthduringchewing. This haspotentantibacterial proper-
ties is highly odoriferous and unstable. Ajoenes are the self-
condensationproductsofallicinandappeartoberesponsible
for garlic’s antithrombotic action. It is generally considered
that allicin and its derivatives are the active constituents of
garlic’s physiological activity. Dried garlic preparations lack
allicin but contain both allinin and allinase. Since allinase is
inactivated in the stomach, dried garlic preparations should
have enteric coating so they pass unaltered through the
stomach to the small intestine where allinin is enzymatically
converted to allicin. Only few commercially available garlic
preparations are standardised for their yield of allicin based
on the allinin content [141].
The consumption of large quantities of fresh garlic
(0.25 to 1.0g/kg or about 5–20 average sized 4g cloves)
has been shown to produce certain beneﬁcial eﬀects [142].
In support of this, a recent double-blind, cross-over study
in moderately hypercholesterolemic men comparing the
eﬀects of 7.2g of aged garlic extract with placebo on blood
lipid levels found a maximal reduction of 6.1% in total
serum cholesterol levels and 4.6% in LDL cholesterol levels
with garlic compared with placebo [143]. However, despite
positive evidence from a number of trials, full endorsement
of garlic for CVD is not forthcoming and many published
studies have methodological shortcomings [142, 144–149].
Some of the problems were that trials were small, they
lacked statistical power, they had inappropriate methods of
randomization, they lackeddietary run-in periods, theywere
of short duration, or they failed to undertake intention-to-
treat analysis. This has led to a cautious approach in the
interpretation of previous meta-analyses [147]. One recent
meta-analysis found that garlic reduces total cholesterol to
a modest extent, an eﬀect driven mostly by the modest
reductions in triglycerides and there was no appreciable
eﬀect on LDL or HDL cholesterol [150].
Garlic has also been studied in hypertension, with no
conclusive result [151]. A meta-analysis of 8 trials suggested
some clinical value in patients with mild hypertension, but
t h ee v i d e n c ew a si n s u ﬃciently good to commend garlic for
routine clinical therapy [149]. Garlic has been shown to have
antiplatelet stickiness activity. This has been documented
in vitro [152], and a new study examined the eﬀect of
consuming a clove of fresh garlic on platelet thromboxane
production. After 26 weeks, serum thromboxane levels were
reduced by about 80% [153]. Thus it may prove to be
of beneﬁt in the prevention of thrombosis. Another trial
showed thatlong-termintakeof300mgdailyofstandardised
garlic powder for more than 2 years improved the elastic
properties of the aorta [154]. In these ways garlic has shown
several beneﬁts to cardiovascular health and needs further
study. Moderate garlic consumption causes few adverse
eﬀects other than bad odour. However, with more than 5
cloves daily, heartburn, ﬂatulence, and other gastrointestinal
disturbances have been reported. Allergic contact dermatitis
has occurred, and patch testing is available when garlic
allergy is suspected [155]. Due to its antithrombotic activity,
garlic should be taken with caution in people on oral
anticoagulants [156].
3.ResearchNeeds
The clinical studies reviewed above are generally not sup-
portive of the use of supplements of these food constituents
although guidelines generally recommend increasing intake10 ISRN Cardiology
Table 4: Summary of recommended lifestyle advice based on
cardiovascular risk groups.
CVD risk Recommendations
High Risk:Clinically
determined ≥20%∗
Intensive lifestyle advice on a
cardioprotective dietary pattern
with a dietitian, physical activity,
and smokingcessation
interventions. Lifestyle advice
should be given simultaneously
with drug treatment.
Medium Risk:Calculated
10–20%
Speciﬁc individualized lifestyle
advice on a cardioprotective
dietary pattern, physical activity,
and smokingcessation. This
lifestyle advice should be given
by the primary health care team
for 3–6 months prior to
initiating drug treatment.
Low Risk:Calculated <10%
General lifestyle advice on a
cardioprotective dietary pattern,
physical activity, and smoking
cessation.
∗People who have had a previous cardiovascular event (angina, MI, angio-
plasty, coronary artery bypass grafts, TIA, ischaemic stroke, or peripheral
vascular disease) or people with certain genetic lipid disorders or people
with DM and who are over 40 years.
Adapted from American Heart Association guidelines for primary preven-
tion of cardiovascular disease and stroke: 2002 updates and New Zealand
cardiovascular guidelines handbook [138, 159].
of fruits and vegetables which are rich in some of these
materials. Omega-3 poly-unsaturated fatty acids may be one
exception where supplements appear to be useful in people
with established CHD. With the other dietary constituents
which may have beneﬁts in the prevention or treatment of
CVD, the evidence from intervention trials is mostly not
suﬃcient to support any deﬁnitive recommendations. Many
of the trials have been too small, and diﬀerent trials have
often used diﬀerent supplements with variable composition
so the meta-analyses of such interventions may not always be
considering the same active compounds. Many of these food
substances do have ingredients with demonstrable phar-
macological eﬀects, but larger clinical trials with properly
standardized materials are needed before any clear conclu-
sions can be drawn. In addition, the potential interaction
of some chemical components, especially ﬂavonoids, with
conventionaldrugsthroughmechanisms suchas modulating
ABCtransporterexpressionmayaﬀecttheabsorption,distri-
bution,andexcretionofdrugs.Forinstance,catechins,found
in tea and red wine, may alternatively inhibit or enhance
P-glycoprotein (ABCB1) function [157], and some of these
compounds such as quercetin found in tea and red wine
are substrates of P-glycoprotein [158]. These interactions
couldimproveabsorptionofpoorlyabsorbeddrugs,butthey
could also lead to drug intoxication and interfere with drug
excretion process so it is important to consider potential
drug interactions if large doses of these materials are given
as supplements.
4.Conclusions
Several common food constituents are thought to inﬂuence
the development and progression of CVD, and this is sup-
portedbyevidenceofpotentiallybeneﬁcialbiologicalactions
and analyses from some observational studies. However, the
evidenceofbeneﬁcial eﬀectsin studiesinvolving supplemen-
tation isgenerally inconclusive,apart from the use ofomega-
3 PUFA in patients with established CAD. Furthermore,
excessive intake of some of the components which may
be taken with these items, such as alcohol, saturated fat,
and glucose, is likely to have harmful eﬀects which may
oﬀset any beneﬁt from the other active ingredients. Until
more deﬁnitive results become available, the best approach
is to recommend a well-balanced diet that includes adequate
fruit and vegetables with moderate amounts of the food
constituents discussed here. A summary of recommended
lifestyle advice for primary and secondary prevention based
on CVD risk groups is showed in Table 4.I ti si m p o r t a n t
to recognize that the current worldwide epidemic of obesity,
diabetes and resulting CVD is related to excessive intake of
calories and animal fats along with reduced physical activity
and supplementation with any additional beneﬁcial food
material is unlikely to overcome these problems unless the
underlying causes are addressed directly.
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